In a patient with NSTEMI who is hemodynamically stable, has a systolic blood pressure ≥90 mm Hg, no right‑ventricular infarction, no severe aortic stenosis, and has not taken a phosphodiesterase‑5 inhibitor recently, can Nitrocontin (extended‑release nitroglycerin) also be given?

Yes, Nitrocontin (extended-release nitroglycerin) can be given to this hemodynamically stable NSTEMI patient, but only in the specific form of intravenous or sublingual nitroglycerin—not as an oral extended-release formulation.

Critical Clarification on "Nitrocontin"

The term "Nitrocontin" in your question appears to refer to extended-release oral nitroglycerin. However, the FDA drug label evidence provided 1 actually describes "Nitrocontin" as tolnaftate 1% antifungal cream for athlete's foot—not a cardiac medication. This is clearly a labeling error in the evidence database. For NSTEMI management, we must focus on actual nitroglycerin formulations.

Guideline-Based Nitrate Recommendations for NSTEMI

Sublingual Nitroglycerin (First-Line)

Patients with NSTEMI and continuing ischemic pain should receive sublingual nitroglycerin 0.3-0.4 mg every 5 minutes for up to 3 doses 2, 3. This is a Class I recommendation with strong evidence support 2, 4, 5.

Intravenous Nitroglycerin (For Persistent Symptoms)

After sublingual dosing, intravenous nitroglycerin is indicated for the first 48 hours after NSTEMI for treatment of persistent ischemia, heart failure, or hypertension 2, 3. This is also Class I, Level of Evidence B 2.

The typical IV dosing starts at 5-200 mcg/min, with a common ceiling of 200 mcg/min 3. Tolerance develops after 24 hours of continuous therapy, requiring periodic dose increases or conversion to non-tolerance-producing regimens 3.

Oral/Topical Extended-Release Nitrates (Limited Role)

Oral or topical nitrates are acceptable alternatives for patients who require antianginal therapy but do NOT have ongoing refractory ischemic symptoms 3. The guidelines emphasize:

• These should be administered in non-tolerance-producing regimens (intermittent dosing with nitrate-free intervals) 3
• Conversion from IV to oral/topical should occur within 24 hours once the patient is stabilized and free of ischemic symptoms for 12-24 hours 3
• It is not appropriate to continue IV nitroglycerin (or start extended-release formulations) in patients who remain free of signs and symptoms of ischemia 3

Absolute Contraindications in Your Patient

Your patient scenario specifically excludes these contraindications, but they bear repeating as they are Class III (Harm) recommendations 3, 6, 3:

1. Systolic BP <90 mmHg or ≥30 mmHg below baseline (Level of Evidence: C)
2. Right ventricular infarction (Level of Evidence: C)
3. Severe bradycardia (<50 bpm) or tachycardia (>100 bpm without symptomatic heart failure) (Level of Evidence: C)
4. Phosphodiesterase-5 inhibitor use within 24 hours (sildenafil), 48 hours (tadalafil), or unknown timing (vardenafil) (Level of Evidence: B/C) 3, 6

The interaction between PDE5 inhibitors and nitrates causes synergistic hypotension that can be life-threatening 7. Research confirms sildenafil/vardenafil interactions resolve by 24 hours, while tadalafil requires 48 hours 7.

Clinical Algorithm for Nitrate Use in Your Patient

For a hemodynamically stable NSTEMI patient (SBP ≥90 mmHg, no RV infarction, no recent PDE5 inhibitor):

1. If ongoing chest pain: Give sublingual NTG 0.4 mg every 5 minutes × 3 doses 2, 4, 5

2. If pain persists after sublingual doses OR if hypertension/heart failure present: Start IV NTG at 5-10 mcg/min, titrate up to 200 mcg/min as needed 2, 3

3. Once pain-free for 12-24 hours: Convert IV NTG to oral/topical long-acting nitrate with nitrate-free intervals (e.g., isosorbide mononitrate 20 mg twice daily with 12-hour gap, or transdermal NTG 0.2-0.8 mg/h for 12 hours on/12 hours off) 3

4. Do NOT use extended-release oral nitrates as initial therapy for active ischemia—they are too slow-acting 3

Important Caveats

• Nitrate therapy should not preclude or delay other mortality-reducing interventions such as beta-blockers, ACE inhibitors, or dual antiplatelet therapy 2, 3
• Recent research 8 demonstrates that nitroglycerin-induced hypotension occurs at similar rates in inferior versus non-inferior STEMI (8.2% vs 8.9%, p=0.73), challenging older concerns about inferior wall MI
• Morphine sulfate 2-4 mg IV may be reasonable for continued chest pain despite maximally tolerated anti-ischemic medications, though it should not replace definitive ischemia management 2, 3, 6

Bottom line: Start with sublingual NTG for active symptoms, escalate to IV if needed, and reserve oral extended-release formulations only for maintenance therapy after stabilization—never as initial treatment for active NSTEMI.